BiVACOR

“We take a personal connection to all of our patients because they’re changing the world for heart failure.” - Daniel Timms, Founder and CTO #TotalArtificialHeart #Innovation

We are excited to share that the first patient in Australia has been successfully implanted with the BiVACOR Total Artificial Heart and surpassed 100 days with the device and discharged from the hospital before receiving a donor heart. “It is incredibly rewarding to see our device provide extended support to the first Australian patient. The unique design and features of the BiVACOR TAH translate into an unparalleled safety profile, and it’s exhilarating to witness decades of work come to fruition, “ said Daniel Timms, PhD, Founder and CTO of BiVACOR. “The Australian patient is the longest to be supported by the BiVACOR TAH implant while waiting for a heart transplant, allowing him to celebrate another birthday, Christmas, and New Year with friends and family, free from the symptoms of heart failure.” Continued Timms, “The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart. Their bravery will pave the way for countless more patients to receive this lifesaving technology.” #TotalArtificialHeart #HeartFailure #MedTech #Innovation

In the first MedTech Talk episode of 2025, host Geoff Pardo speaks with BiVACOR Chief Medical Officer William Cohn about entrepreneurship, innovation, and thinking outside the box. Dr. Cohn discusses his experiences as a driving force behind the Center of Device Innovation at the Texas Medical Center, what influenced him to pursue medical devices, and finding resources in everyday objects. 𝑻𝒂𝒌𝒆 𝒂 𝒍𝒊𝒔𝒕𝒆𝒏 𝒉𝒆𝒓𝒆: https://lnkd.in/eHHaj8Hf #MedTechTalk #innovation #entreprenuer #cardiology #medicaldevice #podcast

The Next Era of Heart Failure Treatment What if we could build a heart that never fails? A human heart is an incredible biological machine, but like any machine, it has limitations: - It wears out. - It can’t be replaced naturally. - It determines how long you live. For decades, attempts have been made to mimic the heart’s natural function with mechanical pumps. But the BiVACOR Total Artificial Heart is taking a different approach: >> Self-regulating blood flow—adapts in real-time to activity levels. >> Rotary pump design—inspired by aerospace engineering and magnetic levitation for durability. >> Designed for long-term function—moving beyond temporary support. We are closer than ever to a future where heart transplants are not the only answer. What do you think will be the most significant shift in cardiac care in the next decade? #HeartMonth #FutureOfMedicine #TotalArtificialHeart #MedicalBreakthroughs #CardiovascularInnovation #OurHearts

The Evolution of Artificial Heart Technology For decades, we’ve had pacemakers, LVADs, and mechanical circulatory support, but a durable, fully functional Total Artificial Heart (TAH) has remained just out of reach. That’s changing. What’s different today: ➡️ Smaller, more efficient artificial hearts—using aerospace-inspired rotary pump technology. ➡️ Continuous blood flow design—eliminating wear-and-tear on mechanical valves. ➡️ Fully implantable systems—working towards removing external drive lines that increase infection risk. The future of heart failure treatment is about more than extending life—it’s about restoring quality of life. #HeartMonth #FutureOfMedicine #CardiovascularInnovation #OurHearts #TotalArtificialHeart

The Heart Transplant Gap: Why It’s Not Enough Every patient with biventricular heart failure is told the same thing: the gold standard is a heart transplant. But what if that’s not an option? The reality of heart transplants: ➡️ More than 3,500 people in the U.S. are on the heart transplant waitlist each year. ➡️ Only 3,000 donor hearts become available annually. ➡️ Many patients won’t survive long enough to receive a transplant. Even for those who do, transplants come with lifelong immune suppression, infection risks, and limited long-term durability. If heart transplants aren’t enough to meet demand, what comes next? That’s the question driving medical device innovation today. Tomorrow, February 7th, is Wear Red Day to bring awareness to the importance of heart health. #HeartFailure #MedicalBreakthroughs #ArtificialHeart #HeartMonth #OurHearts

February is American Heart Month. While heart disease remains the leading cause of death in the U.S., we aim to draw attention to advanced heart disease—specifically, heart failure. Heart failure is one of the most significant challenges in modern medicine, yet many people are unaware of how limited our treatment options currently are. The facts: ➡️ 6.2 million Americans are living with heart failure today. ➡️ 1 in 8 deaths in the U.S. is attributed to heart failure. ➡️ When both sides of the heart fail (biventricular heart failure), the only treatment options are transplant or mechanical support, and donor hearts are in short supply. Despite decades of advancements, we continue to depend on a limited pool of donor hearts to treat a growing population of patients. This month, we’ll delve into the constraints of current treatments and the medical innovations that are shaping the future of heart failure. What do you think is the biggest challenge in treating advanced heart failure today? #HeartMonth #HeartFailure #MedicalInnovation #CardiovascularSolutions #OurHearts

Tomorrow, Dr. William Cohn, BiVACOR’s Chief Medical Officer, will take the stage at 𝗖𝗼𝗻𝘁𝗿𝗼𝘃𝗲𝗿𝘀𝗶𝗲𝘀 & 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 to explore 𝗧𝗵𝗲 𝗣𝗮𝘀𝘁, 𝗣𝗿𝗲𝘀𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗧𝗼𝘁𝗮𝗹 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗛𝗲𝗮𝗿𝘁: 𝗟𝗲𝘀𝘀𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝗧𝗲𝘅𝗮𝘀—a deep dive into the evolution of total artificial heart technology and the groundbreaking progress of the BiVACOR Total Artificial Heart. 📅 January 31st ⏰ 3:50 – 4:20 PM With decades of advancements leading us closer to revolutionizing heart failure treatment, this is a session you won’t want to miss! https://lnkd.in/gi_KDYHG #ArtificialHeart #MedicalInnovation #Cardiology #HeartFailure #FutureOfMedicine

We’re hiring and looking for our Director of Quality Assurance. With key milestones set for 2025, we’re looking for someone passionate and enjoys the fast pace of a startup environment to join our team. Apply today! Learn more here: https://lnkd.in/e7g8gdtk #hiring #qualityassurance #medtech

“Imagine a world where someone with end-stage heart failure no longer has to worry about waiting for a transplant.” BiVACOR had an incredible year in 2024, achieving a major milestone by implanting the BiVACOR Total Artificial Heart in five patients as part of an FDA Early Feasibility Study. Ending the year on a high, the FDA approved expanding the trial to an additional 15 patients – a significant step forward in the future of heart failure treatment. We’re proud to back BiVACOR through our Healthcare Fund III, supported by the Biomedical Translation Fund (BTF), and we’re excited to continue this journey alongside them as they achieve more milestones. BiVACOR, Paul Kelly, Department of Industry, Science and Resources